pay for delay

  • Seroxat pills are seen in this illustration picture taken in Bucharest April 19, 2013. Britain's competition body accused GlaxoSmithKline of market abuse for striking deals with three generic drugmakers that paid them to delay launching cheap copies of its antidepressant Seroxat. GSK, Britain's biggest drugmaker, said it believed it had acted lawfully. If it is found to have broken the law, it could be fined up to 10 percent of its worldwide turnover, which amounted to 26.4 billion pounds ($40.4 billion) in 2012. The move by the Office of Fair Trading (OFT) is the latest example of regulators trying to curb "pay-for-delay" deals, following a series of investigations against drug companies by U.S. and European antitrust officials.   REUTERS/Bogdan Cristel (ROMANIA  - Tags: DRUGS SOCIETY HEALTH)   - RTXYS79
    June 5, 2015  

    The Federal Trade Commission’s recent $1.2 billion settlement over the drug Provigil has brought so-called “pay for delay” deals for generic drugs back into the spotlight. Opponents say these deals delay generic medications to market, costing consumers billions. But drug companies say that the deals help get generics to market by avoiding lengthy patent litigation. NewsHour’s Megan Thompson reports. Continue reading

  • payfordelay
    June 28, 2014  

    Are generic drugs being delayed to market by so-called “pay for delay” deals between drug companies? The deals happen after generic drug companies challenge the patents on brand-name drugs. The settlements include a date that the generic drug can enter the market, and in some cases, a payment from brand company to the generic company. Continue reading